Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eribulin

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in phase 3 breast cancer study

More than two million cases of breast cancer were diagnosed globally in 2022

- PMLiVE

UK study reveals significantly higher risk of second cancers among breast cancer survivors

Breast cancer is currently the most commonly diagnosed cancer in the UK, affecting around 56,000 people annually

- PMLiVE

AstraZeneca’s Truqap plus Faslodex receives CHMP recommendation for advanced breast cancer

More than 550,000 new cases of breast cancer were diagnosed in Europe in 2022

- PMLiVE

Eisai and BioArctic sign research evaluation agreement for potential new Alzheimer’s treatment

AD is the most common form of dementia, which affects around 55 million people globally

- PMLiVE

Sanofi’s Rezurock fast-tracked by NHS for rare chronic graft versus host disease

Around 400 stem cell or bone marrow transplant patients will develop the condition each year in England

- PMLiVE

ICR scientists identify new way to study important driver of breast cancer

Researchers used a technique to identify specific molecular details of biotin-labelled proteins

- PMLiVE

ICR researchers reveal how advanced breast cancers become resistant to hormone therapy

F404 mutations combined with pre-existing mutations caused resistance to fulvestrant

- PMLiVE

UK government approves digital pathology for cancer screening programmes

The approval follows a study that showed digital pathology was as effective as microscopy

- PMLiVE

WHO reveals growing global cancer burden in line with World Cancer Day

The three most commonly occurring cancers in 2022 were lung, breast and colorectal cancer

- PMLiVE

Pfizer’s Talzenna recommended by NICE for advanced breast cancer

An estimated 300 patients will be eligible for treatment with the PARP inhibitor

- PMLiVE

Johnson & Johnson to acquire ADC specialist Ambrx Biopharma for approximately $2bn

The deal includes an ADC candidate in clinical development to treat advanced prostate cancer

- PMLiVE

MHRA approves Menarini Stemline’s Korserdu for advanced or metastatic breast cancer

More than 55,000 new cases of breast cancer are diagnosed each year in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links